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”The world is full of magical things  
patiently waiting for our wits to grow sharper” 
 
- Bertrand Russell 
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ABSTRACT 
 
 
The inflammatory state of chronic kidney disease (CKD) leads to increased susceptibility to infections 
and cardiovascular complications. In this thesis we aimed to investigate development of inflammatory 
properties at different stages of CKD and changes in innate immunity as well as cardiac structure. 
Fibroblast growth factor 23 (FGF23), a phosphaturic hormone known to impact cardiovascular 
outcome and inflammatory markers in CKD was also analyzed.  
 
In the first paper1 a cross sectional study of transmigrated monocytes in patients with advanced CKD 
was performed. Patients with CKD had an increased percentage of CD16+ monocytes, distorted TNF-α 
and IL-10 levels and a significantly higher level of fractalkine (CX3CL1). This inflammatory profile 
may in part mediate the altered immune response in CKD.  
The aim of the second paper2, was to investigate end organ damage to the heart of the pro-
inflammatory state of CKD by evaluating cardiac structure and function in patients with CKD stages 
2-5, compared with healthy controls in the PROGRESS cohort. Transthoracic echocardiography and 
Tissue Doppler Imaging (TDI) were performed to describe cardiac dimensions such as left ventricular 
mass, wall thickness and diastolic and systolic function. CKD patients had a higher prevalence of 
left ventricular hypertrophy (LVH) and alterations in systolic and diastolic myocardial function 
compared to the healthy controls.   
In the third paper, inflammatory changes and altered monocyte function in patients with CKD stage 
2-3 was compared to healthy controls in the PROGRESS cohort at baseline and at follow up after 3 
and 5 years. Monocytes from CKD patients showed early functional abrasions, with altered adhesion 
molecule expression and significantly lower fMLP-induced upregulation of CD11b and decreased 
level of L-selectin (CD62L). CKD patients also had lower oxidative burst in response to fMLP over 
time as well as elevated pro-inflammatory cytokines; TNF-α, RANTES and IL-12. These findings 
suggest that a transformation of monocyte function occurs at an early phase of renal impairment and 
may together with increased plasma levels of pro-inflammatory cytokines contribute to the higher 
vulnerability of CKD patients to comorbidities.  
Our primary objective of the fourth paper was to characterize the altered chemokine profile and 
leukocyte function at CKD stages 2-5 and investigate correlations between these markers and levels of 
FGF23. Elevated levels of FGF23 in CKD are associated to worse outcome and cardiovascular 
complications. FGF23 has also been described to interact in inflammatory processes. FGF23 was 
significantly elevated in the CKD group, and correlated to GFR, PTH, urinary albumin excretion 
(UAE) and phosphate as well as to the expression of IL-12 and RANTES.  In vitro incubation of 
leukocytes with FGF23 reduced CD11b expression in resting as well as in fMLP-stimulated 
granulocytes. Together this indicates an influence of FGF23 on leukocyte transmigration and an 
interference with chemokine signaling in CKD.   
 
In Summary; several factors are involved in inflammation in CKD. Better understanding of 
immunologic mechanisms and altered cellular function at different stages of CKD might help to 
explain the enhanced risk of cardiovascular disease as well as the increased susceptibility to infections. 
With improved knowledge of the inflammatory processes accompanying CKD we might obtain 
diagnostic and prognostic tools to improve clinical outcome. 
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1 GENERAL INTRODUCTION - CHRONIC KIDNEY DISEASE  
 
 
1.1 EPIDEMIOLOGY AND ETIOLOGY 
 
Chronic kidney disease (CKD) is a cumbersome and life threatening disorder. Renal failure 
exposes the patients to an accelerating degree of inflammation and disabling uremia. 
Furthermore this condition brings additional sickness and death through higher incidence of 
cardiovascular morbidity and mortality3–5 as well as increased susceptibility to infections6. 
Treatment of end-stage renal disease (ESRD) with renal replacement therapy (RRT), achieved 
by hemodialysis, peritoneal dialysis or kidney transplantation, can be lifesaving. RRT is 
expensive and not readily offered outside the industrialized world. Demand and costs of RRT 
are increasing each year7,8. In Sweden, the number of dialysis patients has increased by 35 % 
since the millennium9. In the industrialized world the plethoric geriatric group mediates a 
steadily growing incidence of RRT in the population10,11. Patients with CKD are a heterogenic 
group with the declining renal function due to many different etiologies9, where diabetic 
nephropathy, nephrosclerosis and glomerulonephritis constitute the largest diagnosis groups.  
 
1.2 CLASSIFICATION OF CHRONIC KIDNEY DISEASE 
 
National kidney foundation and the Kidney Disease Outcomes Quality Initiative (NKF/ 
KDOQI) published an unifying classification and definition of CKD in 200212, and in 2013 an 
updated version was launched. Based on glomerular filtration rate (GFR) there are currently 
five stages or grades (G) where grade 3 is subdivided into 3a and 3b (Table 1). Structural or 
functional abnormalities of the kidney with a duration exceeding a time frame of three months 
is required to meet the definition. In the absence of evidence of kidney damage, GFR category 
G1 and G2 do not fulfill the criteria for CKD.  
 
GFR  
category 
GFR  
(mL/min/1.73 m2) 
Terms 
G1 >90 Normal or high 
G2 60-89 Mildly decreased 
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
Table 1. GFR categories according to KDIGO guidelines  12,13 
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1.3 GLOMERULAR FILTRATION RATE ESTIMATIONS 
 
 
Inulin, a fructose polysaccharide, is considered the gold standard for GFR measurement14. 
Other frequently used methods to measure GFR are 125I-iothalamate, 51Cr-EDTA, and 
iohexol15. For every day clinical use however, these methods are too costly, time consuming 
and not without adverse effects. A more convenient and less expensive substitute to estimate 
GFR are endogenous substances such as creatinine, urea and cystatin C measured in urine or 
blood16. Serum creatinine (S-Cr) is the cheapest and most widely used alternative, but has 
multiple disadvantages. The S-Cr level is affected by the individual muscle mass, proportion 
of recently ingested meat and the body’s fluid homeostasis17. 
Over the years, several attempts to develop a reliable equation to estimate GFR from the S-Cr 
have been made. The Cockcroft-Gault formula18 estimates the creatinine clearance, which is 
not corrected by body surface area, and thus the absolute value of the filtration rate. Due to 
the increased creatinine secretion, the creatinine clearance usually overestimates GFR when 
the GFR is low. With these limitations taken in account the Swedish agency for health 
technology assessments workgroup stated in their report on estimating renal function from 
2014 a general recommendation to discard this method19,20 
The MDRD formula was launched 1999 and revised 200621, standardizing the GFR to body 
surface area (ml/min/1.73m2) and based on the Modification of Diet in Renal Disease 
(MDRD) study22. The CKD-EPI ( Chronic Kidney Disease Epidemiology Collaboration) 
formula is another more recently developed equation and obtains more accurate eGFR values 
in the high eGFR range (>60 ml/min/1.73 m2) as well as eGFR values in the lowest range23. 
In research, the MDRD equation is more widely established and believed to give a more 
accurate estimate of the GFR, particularly for overweight and geriatric individuals16,21. Both 
the MDRD and the CKD-EPI equations include variables for age, gender and race and have in 
direct comparison to Cockcroft-Gault23 and creatinine clearance measured from 24-hour urine 
collections demonstrated superiority24. The revised Lund-Malmö GFR estimating equation 
that combine creatinine and cystatin C and has in a large Swedish cohort outperformed 
MDRD and CKD-EPI25,26. 
Cystatin C, a proteinase inhibitor produced by all human cells and dependent on glomerular 
filtration has become an increasingly popular endogenous marker for GFR. It offers better 
precision among patients with mild CKD and is less sensitive to diet, gender, age and body 
configuration27. However, cystatin C eGFR should not be used on patients on medication with 
glucocorticoids or with hyperthyroidism in whom the levels are significantly increased.  
At extremities in age or body configuration, severe malnutrition or obesity, in pregnancy, in 
vegetarian or vegan diet, muscle diseases or rapidly changing renal function all eGFR 
methods have their limitations.  
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2 BACKGROUND 
 
 
2.1 RISK FACTORS FOR CKD 
  
Already at the age of 25 years the GFR starts to decline with a pace of about 1 ml/min per 
year. There is a considerable inter-individual variation in the progression rate but midst 
patients with CKD, the progression rate is usually more rapid than in the general 
population28,29. By targeting blood pressure control, lowering albuminuria and optimizing 
body fluid volume and electrolyte balance, nephrologists try to delay or halt the progression 
rate, preventing patients from developing uremia and premature start of dialysis.  The kidneys 
are exposed to multiple potentially damage inflicting causes ranging from exogenous toxins to 
life style factors and metabolic or inflammatory diseases. With these repetitive strikes at renal 
function over time, continuous loss of nephrons follow and glomerular hypertension develops 
in the remaining nephrons that try to compensate the overall loss of function by 
hyperfiltrating. This hyperfiltrative state leads to increased urine albumin excretion and 
enhanced mesangial cell proliferation as well as an elevated pro-inflammatory cytokine 
production30,31. Consequentially, renal fibrosis and nephrosclerosis develops. 
 
 
2.2 CARDIOVASCULAR COMPLICATIONS IN CKD 
 
CKD generally aggravates arteriosclerosis and already at modest level of CKD (stage 1 – 2) 
cardiovascular risk increases32,33. Cardiovascular disease (CVD) poses the greatest risk of 
premature death seen among patients with CKD, leading to 40% of all deaths among 
European dialysis patients34. The incidence of left ventricular hypertrophy as well as 
congestive heart disease and coronary heart disease increase with subsequent loss of renal 
function35. Risk of cardiovascular death is up to 30 times higher in dialysis patients than in 
age- and sex-matched controls in the general population36. Diabetes mellitus, hypertension, 
hypercholesterolemia, smoking and physical inactivity are well established traditional risk 
factors for CVD and are highly prevalent in patients with mild CKD (stage 1 – 3)37. Patients 
with CKD are challenged with additional pathological processes such as endothelial 
dysfunction, oxidative stress, low grade chronic inflammation, fluid overload, acidosis, AV-
fistula complications, anemia and alterations in calcium and phosphate levels, as well as 
vascular calcification and secondary hyperparathyroidism38,39. In spite of all these striking 
data, CVD is frequently underdiagnosed and undertreated in patients with CKD40. These 
patients also display a combined atherosclerotic pathophysiology with both damaging intima 
located plaques and smooth muscle cell hyperplasia that in time develop extensive 
calcifications in the media layer of the arteries41–43. The entire vascular apparatus from 
coronary arteries to aorta and heart valves get widely infested with calcified plaques.  
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In CKD patients, lipid abnormalities are found early on and changes character as progression 
of renal failure continues44.  
Dyslipidemia in renal disease commonly exhibit an atherogenic profile with elevated LDL, 
reduced HDL and high triglycerides (TG). Increased glomerular permeability leads to loss of 
lipoprotein lipase and albuminuria stimulates hepatic synthesis of lipoproteins45–47. 
Inflammation suppresses the anti-oxidative action of HDL which leads to higher amounts of 
oxidized LDL48. Lipid-lowering medication has shown benefits in the early to moderate CKD 
population, probably related to the degree of LDL reduction, rather than the pleotropic effects 
of statins49. Treatment with lipid-lowering agents only moderately reduce atherosclerotic 
events in individuals in late CKD without being proven to alter mortality50. Left ventricular 
dysfunction (LVD) predicts congestive heart failure (CHD) and the presence of CHD predicts 
an exceedingly high mortality rate in dialysis patients51. Risk factors of LVD are multiple in 
CKD; ranging from volume overload, hypertension, inflammation, anemia and AV-fistulas 
with high blood flow that increases cardiac output52–54. LVH can be subdivided in concentric 
hypertrophy, concentric remodeling and eccentric hypertrophy. Eccentric hypertrophy may be 
a consequence of increased preload triggered by anemia and/or intra vascular volume 
expansion (salt and fluid loading) while concentric hypertrophy frequently results from 
afterload augmented by hypertension or increased systemic arterial resistance (secondary 
effect to RAS-activation or vessel calcifying HPT)55. The adjusted relative risk (RR) of death 
in a dialysis population is greatest for patients with eccentric hypertrophy56. N-terminal pro-
brain natriuretic peptide (NT-proBNP) is used as a marker of CHF in non-renal patients where 
an increase leads to inhibition of the renin-angiotensin-system, vasodilatation and 
natriuresis57–59. With loss of renal function proBNP clearance is reduced, which leads to 
rapidly increasing levels. However even after correcting for volume overload, NT-proBNP is 
a prognostic factor of LVD and death in CKD60–62 just like other newer cardiovascular 
prognostic biomarkers such as cardiotrophin and GAL-3 also have been shown to, after 
adjustment, be applicable in CKD63,64. Combined heart and kidney failure has been named the 
cardiorenal syndrome (CRS), a troublesome symptomatic condition requiring high 
hospitalization frequency and displaying a discouraging mortality rate65,66 An inflammatory 
etiology to CRS has been proposed with enhancing inflammatory burden from oxidative 
stress on the endothelium67.  
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2.3 ECHOCARDIOGRAPHY IN CKD PATIENTS  
 
Cardiac imaging in CKD can monitor clinical progress, provide prognostic data and stratify 
risk as well as assess cardiac effects of therapies such as fluid management, dialysis and renal 
transplantation. 74% of patients with CKD stage 5 display evidence of LVH at the initiation 
of dialysis treatment68. Intrinsic cardiac disease can nevertheless be complicated to diagnose 
in CKD due to comorbidities as diabetes, hypertension or old age, all making symptom 
patterns less obvious. Additional CKD specific circumstances with volume overload or 
anemia further confound the clinical evaluation. Accurate diagnosis is essential for initiation 
of appropriate therapy. 2D transthoracic echocardiography is inexpensive, non-invasive and 
widely available, hence frequently regarded as the first-line investigative tool for determining 
cardiac function and structure. It classifies systolic function through evaluation of ejection 
fraction (EF) and fractional shortening (FS), as well as registers change in LV geometry 
according to LV end-diastolic volume, wall thickness and left ventricular mass index (LVMI). 
2D echocardiography can identify structural changes associated with poor prognosis69 and 
differentiate between type of hypertrophy. However, this method can be prone to inaccuracy 
as some measurements are derived rather than actual measures, it has low sensitivity in 
detecting subtle alterations in left ventricular function and is undermined by low 
reproducibility. Impaired relaxation and compliance of the left ventricle generally result in 
diastolic dysfunction. Diastolic function can be estimated by 2D echocardiography with 
comparison of blood flow across the mitral valve during early diastole (E, passive filling) and 
late diastole (A, atrial contraction). Under normal conditions, passive filling is greater than 
filling during atrial contraction, giving an E:A ratio of 1-2. A ratio < 1 signifies impaired 
relaxation whereas E:A > 2 indicates a restrictive filling (limited filling under late diastole). 
Elevated left atrial volume (LAV) predicts all-cause mortality and is a surrogate marker for 
diastolic dysfunction in CKD70. 
Tissue Doppler imaging (TDI) has the ability to detect myocardium wall motion 
abnormalities even when EF is in the normal range. These segmental contraction-relaxation 
disturbances of the myocardium affect the three-dimensional myocardium distortion under 
systole (longitudinal shortening, radial twist and circumferential contraction). TDI is 
especially reliable in detecting longitudinal and radial strain, amplifying the high-velocity 
signals from heart valve and myocardium describing systolic and diastolic function from 
tissue velocity. An altered longitudinal strain inclines worse prognosis despite preserved 
EF71,72. Furthermore, TDI can assess the vertical motion of the mitral annulus; an E/e´ ratio 
(i.e. mean early diastolic transmitral velocity (E) to mitral annulus diastolic velocity (e´)), ≥13 
is indicative of diastolic dysfunction. Less available but somewhat superior; 3D transthoracic 
echocardiography produces assessments of ventricular volume and mass from full LV 
geometry data comparable to MRI results, not risking the overestimations of EF or 
underestimation of diastolic volumes like the 2D technique. 
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2.4 KIDNEY-BONE-AXIS AND FGF23 
 
CKD-MBD or chronic kidney disease – mineral bone disorder, is a condition characterized by 
vascular calcification, biochemical abnormalities, fractures and increased mortality risk. 
Derived from osteocytes and osteoblasts, levels of fibroblast growth factor 23 (FGF23) are 
elevated at an early stage of renal failure73. FGF23 is a phosphaturic hormone which reduces 
the synthesis of active 1,25-dihydroxy vitamin D374. In CKD renal handling of phosphate is 
compromised leading to a compensatory rise in FGF23 and development of secondary 
hyperparathyroidism75–78. FGF23 appears to be a more sensitive biomarker of early kidney 
disease than creatinine and enhances phosphate secretion through binding to the tubular FGF-
receptor 1c and the Klotho co-receptor in CKD stages 2-3. In addition, FGF23 simultaneously 
inhibits 1α-hydroxylase and stimulates 24-hydroxylase causing a decrease in circulating 1,25-
dihydroxy vitamin D levels and also appears to reduce parathyroid hormone (PTH) secretion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The effect of FGF23 on target organs. 
 
 
 
 
 
 
 
 
Cardiac remodelling 
LVH 
PTH secretion ↓ 
P excretion ↑ 
1α hydroxylase ↓ 
24 hydroxylase ↑ 
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Moderate changes of FGF23 are commonly seen in CKD 2-3 but a markedly elevated level is 
found in ESRD79. Changes in the levels of FGF23 in chronic renal failure have been shown to 
independently predict CKD progression in renal disease78. Adverse outcomes including 
cardiovascular disease (CVD) and mortality have been linked to higher systemic levels of 
FGF-2380–83. FGF-23 has been shown to enhance cardiovascular dysfunction, through diverse 
mechanisms ranging from impaired vasodilatation, enhanced dyslipidemia, heart valve and 
coronary vessel calcification, direct myocyte damage and LVH84–89.  
Circulating FGF23 levels are increased in heart failure and cardiomyocytes have been found 
to produce FGF23 which theoretically might have a paracrine effect that mediates adverse 
cardiac remodeling in the setting of heart disease90–92.  
Development of LVH can be abrogated by blocking of FGF23 binding to Klotho-independent 
FGFR4 activation despite presence of severe hypertension93,94. Klotho deficiency in CKD is 
in part related to systemic and renal inflammation and vascular calcification95,96. FGF23 
stimulates the RAAS-system97 and alter calcium trafficking  in cardiomyocytes resulting in 
increased contractility, hypertrophy and arrythmogenesis98,99. FGF23 has been described to 
interact in metabolic processes such as inflammation, obesity, insulin resistance and iron 
homeostasis83,100–107. Recent studies have implied diverse effects of FGF23 on inflammation 
in CKD101,108. FGF23 associations to inflammatory markers have been described in both CKD 
and non CKD cohorts100–103,109 The relationship between FGF23 and innate immunity appear 
to be more complex than previously assumed and would benefit from further investigations 
including influence of FGF23 on effector cell function. 
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2.5 INNATE IMMUNITY 
 
The initial phase of a immune reaction to invading pathogens is often referred to as the innate 
immune response and largely depends on complement activation and neutrophil 
mobilization110. Exposure to bacterial peptides activates the complement cascade which 
surges a proteolytic reaction targeting the microorganism and co-stimulates the key effector 
cells; the neutrophils.  Neutrophils have receptors that directly recognize both complement 
(C3b, C5a) and bacterial peptides. Circulating neutrophils that are exposed to microbes 
transform to a primed state, leave the circulation and enter the site of microbiologic invasion, 
where they develop more specific properties, such as phagocytosis and ability to discharge 
inflammatory mediators111. Neutrophils orchestra the innate but also the adaptive immune 
response by releasing pro-inflammatory  substances112. A subsequent step in the innate 
immune response is the recruitment of other inflammatory cells. A chemotactic gradient is 
developed with peak concentrations of chemokines closest to the inflamed area. This gradient 
leads the way for the, due to their slower onset of extravasation, casually late entering 
monocytes. Monocytes have a longer survival than neutrophils and rapidly develops into 
macrophages on arriving at sites of inflammation113 where they participate in phagocytosis 
and generates oxidative burst114. Stimulated macrophages release IL-12 and TNFα, both 
mediating sustained leukocyte transmigration and provoke the liver to produce systemic C-
reactive protein (CRP)115. 
 
 
2.6 LEUKOCYTE EXTRAVASATION AND TRANSMIGRATION 
 
Leukocytes exercise their physiological and pathophysiological effect extravascular after 
adhering to the endothelium and transmigrating into the intima or the subendothelial space. In 
order to practice their local defense mechanisms they need to get recruited and leave the 
circulation through several consecutive steps: rolling, activation, firm adhesion and 
transmigration (Figure 1). The first step is dependent on adhesion molecule interaction 
between the neutrophil and the endothelium of the vessel wall. This process, called tethering, 
is mediated by selectins, allowing the neutrophil to scan the endothelium for the presence of 
G-protein coupled receptors that activate a second phase of integrin-mediated adhesion. Once 
firmly adhered to the endothelium, the neutrophil squeezes through diapedesis into the 
extracellular matrix and onward subsequent transmigration guided by a chemoattractant 
gradient directing them to the distinct inflammatory target zone113,116. 
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Figure 2 Extravasation and transmigration of monocytes. 
 
 
 
2.7 ADHESION MOLECULES: INTEGRINS AND SELECTINS 
 
The integrin family members are membrane receptors that anchor the extracellular 
environment (matrix or other cells) with the intracellular cytoskeleton. There are three 
subtypes of integrins grouped according to their type of β subunit117. The most abundant 
integrin found on leucocytes is β2 (CD18).  At least three different α subunits have been 
described to bind to the β2-integrin. The CD11b/CD18 combination is predominantly 
expressed on monocytes, granulocytes and macrophages. Under non inflammatory 
circumstances peripheral neutrophils and monocytes express a low amount of surface 
CD11b/CD18 and keep the molecules stored in intracellular granulae. Activation of cells 
rapidly recruit CD11b/CD18 to the surface, making CD11b/CD18 a reliable marker of 
initiated adhesion leading up to transmigration of neutrophils117–120. The first interactions 
between leukocytes and endothelial cells are mediated by selectins. Selectin family 
members, L-, P- and E-Selectin, capture passing leucocytes in the bloodstream and initiate 
their deceleration along the vessel wall. This adhesion is initiated by weak interactions that 
produce a characteristic "rolling" motion of the leukocytes on the endothelial surface. P-
Selectin and L-Selectin, also called CD62, act in concert and are essential for these initial 
interactions. Different endothelial stimuli induce an up-regulation of adhesion 
molecules117,120. Since they mediate cell adhesion, intergrins and selectins participate in cell 
development, proliferation, migration and apoptosis. Deficit or aberrant expression of specific 
adhesion molecules might contribute to inflammatory disease as well as to tumor 
development117,121. 
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2.8 OXIDATIVE METABOLISM AND ROS PRODUCTION 
 
At microbial invasions, phagocytic cells produce reactive oxygen species (ROS) as a defense 
mechanism for intracellular killing of bacteria67,122. Macrophages and neutrophils generate 
ROS through activating the NADPH oxidase enzyme complex, thus reduce oxygen O2 to 
reactive superoxide (O2-). This process is referred to as the respiratory burst or oxidative 
metabolism. Further processed by SOD2, glutathione peroxidase and catalase, superoxide is 
converted to highly reactive hydrogen peroxide (H2O2)123.  
 
 
2.9 CHEMOATTRACTANTS, CHEMOKINES AND CYTOKINES 
 
  
Chemoattractants are molecules signaling an ongoing inflammatory event in the body. 
Products from the complement cascade (C3a, C5a), bacterial fragments (fMLP, LPS) and 
chemokines are all considered chemoattractants.118  
Chemokines are small either soluble or membrane bound messenger molecules produced by 
most leukocytes as an inflammatory response after encounters with microorganisms or pro-
inflammatory cytokines such as TNFα or IL-1. They mediate up-regulation of adhesion 
molecules, serve as chemoattractant factors and promote recruitment of inflammatory cells. 
By binding to sugar residents in the extracellular matrix they gradually get captured at the 
inflammatory site124. 
Cytokines are soluble secreted proteins produced in response to an antigen and participate in 
cell growth, activation and differentiation. Based on cysteine residue positioning, chemokines 
divide into two subfamilies, CXC and CC chemokines. Neutrophils respond strongly to CXC 
chemokines while many CC chemokines specifically attract macrophages and T-cells110. 
Cytokines are produced by practically all cells involved in innate immunity and a disturbed 
balance between pro- and anti-inflammatory cytokines can result in tissue damage125. Since 
cytokines can stimulate a cascade of other cytokines from a variety of cell types they rarely 
act alone and are reliant on binding proteins that both protect them from degradation and 
serve as an extracellular cytokine reservoir. Some cytokines have predominantly paracrine 
local effects while others operate systemically126.  
The chemokine fractalkine or CX3CL1, displays a unique transmembraneous domain that 
keeps it anchored to the endothelial cell. Proteolysis generates a soluble circulating 
chemotactic active form of fractalkine. Both the membrane bound and soluble type mediates 
selectin and integrin independent adhesion and chemotaxis127,128. CD16+ monocytes 
particularly rely on the fractalkine pathway to endeavor extravasation129. There are data 
suggesting that fractalkine exhibit a monocyte supporting function resulting in increased cell 
survival in inflammation as well as a capability to protect plaque organized monocytes from 
apoptosis. This might imply a role of fractalkine in the development of vascular disease130.  
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The chemokine RANTES (Regulation on activation, normal T and secreted), also called 
CCL5, orchestra the recruitment of inflammatory cells such as monocytes, dendritic cells, 
neutrophils and macrophages. With the help of cytokines (in particular, IL-12 and IFNγ), 
RANTES also induces the proliferation and activation of certain natural-killer cells and 
enhances the histamine release from eosinophils as well as affects migration of T-cells and 
monocytes131. RANTES induce expression of integrins and metalloproteinases that are 
involved in movement through the endothelial basement membranes and tissues131.  High 
levels of RANTES is associated with a wide range of immune-mediated diseases including 
glomerulonephritis and interstitial nephritis132,133. Blocking of RANTES during early phases 
of chronic ischemia has been shown to mediate decreased neutrophil and macrophage 
recruitment to infarcted tissue leading to improved cardiac function and survival in murine 
studies134.  
Pro-inflammatory cytokine TNFα has been regarded as a superior regulator of the cytokine 
cascade that provides a rapid form of host defense against infection but is fatal in excess. 
Although produced by monocytes, T-lymphocytes, fibroblasts and neutrophils in acute and 
chronic inflammation the major cellular origin of TNFα is activated macrophages135,136. TNFα 
activates neutrophils and mediates neutrophil adherence, chemotaxis, degranulation and 
oxidative burst137. Inducing vasodilatation, increased vascular permeability and promoting 
intravascular coagulation, TNFα play a central role in sepsis and organ failure112,113,. TNFα 
exhibit a pivotal role in regulating both pro- and anti-inflammatory mediators. TNFα is highly 
pleotrophic with effects on insulin resistance, lipid metabolism, coagulation and endothelial 
dysfunction138. It should be noted however, that the association between TNFα and CRP is 
rather weak139. Hence, circulating levels may be affected by a number of different factors and 
that circulating TNFα levels may not reflect biologic activity at the tissue level.   
Systemically acting Interleukin (IL)-6 has a dual role, both as a pro-inflammatory cytokine 
associated with development of atherosclerosis and progression of ERSD80,138 but also as an 
anti-inflammatory cytokine downregulating IL-1 and TNFα as well as increasing 
glucocorticoid synthesis and reduces IFNγ with the net result pointing towards a superior anti-
inflammatory role140.  
Produced early in the infectious process predominantly by monocytes and dendritic cells, IL-
12 is a pro-inflammatory cytokine that has a central function in the initiation and regulation of 
the induction of cell-mediated immunity. IL-12 is an important regulator of the differentiation 
of native T cells into Th1 cells, which is crucial in determining resistance and the type of 
reaction that will be elicited in response to a particular pathogen141.  
Because of their synergistic roles in stimulating inflammation, IL-12, IFNγ - and TNFα are 
considered to be major pro-inflammatory cytokines 141.  
IL-10 is a cytokine produced by monocytes and T-lymphocytes. It inhibits monocyte, 
macrophage and NK cells production of pro-inflammatory cytokines. IL-10 has an anti-
inflammatory profile and it also enhances B-cell survival, proliferation, and antibody 
production142.  
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IL-10 can block NF-κB activity and is capable of inhibiting synthesis of pro-inflammatory 
cytokines such as IFN-γ, IL-2, IL-3, TNFα and GM-CSF made by macrophages and 
regulatory T-cells. Decrease in IL-10 expression results in inadequately 
regulated TNFα levels as IL-10 regulates the TNFα-converting enzyme. As a result, TNFα 
levels rise and drive inflammation143.  
Bacterial peptides triggers extravasation of leukocytes144 and the bacterial tripeptide N- 
formyl-methionyl-leucyl-phenylalanine (fMLP) is regularly used as a chemoattractant in 
studies of leukocyte activation and chemotaxis. By docking to G-protein coupled receptors 
several reactive pathways are initiated, inducing many different inflammatory responsive 
cellular functions including migration and cytokine production122,145,146.  
 
 
 
Figure 3 The innate and adaptive immune systems 
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2.10 INFLAMMATORY CELLS IN CKD 
 
Uremic toxins affect leukocytes in CKD patients. Altered leukocyte adherence to the 
endothelium, impaired chemotaxis, weakened phagocytosis and decreased activity of 
inflammatory cells all occur in CKD147–150. The persistently activated immune system in CKD 
is mirrored by a maladaptive cytokine expression pattern151–153. Activated monocytes have 
been suggested to play an important role in the development of atherosclerosis. Pro-
inflammatory subgroup CD16+ monocytes have been independently associated with 
cardiovascular events in a non-dialysis CKD cohort which might imply this subpopulations 
involvement in human arteriosclerotic development154 Inflammatory triggered monocytes 
enhance their intracellular production of oxygen radicals as well as up-regulate adhesion 
molecules that enables them to infiltrate the endothelial wall155,156. Neutrophils and 
monocytes from patients with advanced CKD have impaired expression of 
CD11b/CD18157,158 There is increasing evidence for a causative connection between 
inflammatory markers with oxidative stress and cardiovascular disease and progression of 
renal failure67,80,159.  
 
 
 
2.11 CHEMOKINES AND CYTOKINES IN CKD 
 
Without showing overt clinical symptoms of infection or visible active inflammation, CKD 
patients display a plasma profile with elevated levels of IL-1, IL-6, TNFα and CRP138. This 
subclinical persistent state of inflammation increase mortality risk and incident cardiovascular 
complications160–162. Research has pinpointed significant alterations in both the adaptive and 
innate immune responses in CKD138,163,164. Cytokine overflow induce fibrosis and incite 
monocyte infiltration eventually causing apoptosis and glomerulosclerosis165. In CKD, 
presence of renal tissue invading macrophages and myofibroblasts is associated with the 
degree of renal function. Macrophages produce pro-inflammatory cytokines such as IL-6 and 
TNFα 166. During the interdialytic interval, the cytokine production from monocytes in 
dialysis patients is normal, although these cells release large amounts of pro-inflammatory 
cytokines under stimulation. In general, IL-12 levels are increased in CKD patients with or 
without dialysis therapy, the elevated levels are probably reflecting a reduced renal clearance 
but also an increased production from DCs that are stimulated by uremic toxins and oxLDL. 
Elevated serum levels of IL-12 have been shown in the sera of chronic HD patients, and the 
overproduction of IL-12 has been associated with accelerated apoptosis of monocytes and T 
cells167,168. Nevertheless, increased IL-12 levels were associated with improved survival in a 
large cohort of patients on dialysis169,170.  
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3 AIMS 
 
The overall objective of this thesis was to gain knowledge about changes in innate immunity 
and cardiac structure in patients with different stages of chronic kidney disease and 
investigate if FGF23-levels and the pro-inflammatory state of CKD in part catalyze the 
adverse clinical outcomes seen in renal insufficiency. 
 
 
The specific objectives were to: 
 
 
Paper I  
 
Investigate the expression of CD16+ and CX3CR1 on peripheral and in vivo extravasated 
monocytes in patients with CKD stage 4-5 and in parallel measure levels of inflammatory 
cytokines in peripheral blood and in the interstitium. 
 
 
Paper II 
 
Investigate if mild-to-moderate CKD patients exhibit alterations in cardiac structure and 
systolic and diastolic function in comparison to patients in advanced CKD as well as to 
healthy controls. 
 
 
Paper III 
 
Investigate monocyte function in terms of adhesion molecule expression and oxidative 
metabolism in patients with mild-to-moderate CKD as compared to healthy controls and 
follow the disease progress over 5 years.  
 
 
Paper IV 
 
Investigate the inflammatory profile in a cross-sectional study of CKD stage 2-5 and examine 
the relationship between FGF23 and immune modulators as well as if FGF23 exposure in 
vitro directly modifies the phenotype of granulocytes and monocytes.  
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4   METHODS 
 
This is a general overview of the methods used in the present thesis. For detailed descriptions 
please refer to each individual article. 
 
4.1 COHORT CHARACTERISTICS 
 
Patients with CKD in all studies were recruited from the Department of Nephrology at the 
Karolinska University Hospital, Solna, Sweden. Informed consent was obtained from all 
patients. All participants gave informed written consent and the study was approved by the 
local ethical committee at the Karolinska University Hospital, Stockholm, Sweden. 
 
 
4.1.1 Paper I – The skin chamber cohort 
 
Included 12 patients with CKD stage 4-5ND (MDRD eGFR < 20 ml/min x 1.73 m2) with a 
mean age of 61 ± 6.2 years. The aetiology of renal impairment ranged from 
glomerulonephritis, interstitial nephritis, adult polycystic kidney disease, amyloidosis and 
nephrosclerosis. Patients with known active systemic inflammatory disease, infectious 
disease, diabetes mellitus as well as those prescribed antibiotics, corticosteroids, non-steroid 
anti-inflammatory drugs, statins, warfarin or immunosuppressive agents were excluded.       
12 age- and gender-matched healthy controls with a mean age was 60 ± 8 years and eGFR     
> 80 ml / min x 1.73 m2 were included as a control group.  
 
4.1.2 Paper II – IV The PROGRESS cohort 
 
Paper II-IV included patients from the PROGRESS cohort, a prospective observational study 
originally designed to detect markers of progression of renal failure. Data from Group 1 was 
only collected for year 0.  
 
Table 1 Inclusion and exclusion criteria of the PROGRESS cohort.  
 Group 1 (n= 49) 
Advanced CKD 
Group 2 (n= 54) 
Mild-to-Moderate 
CKD 
Group 3 (n= 54) 
Healthy controls 
Inclusion criteria  GFR < 20ml/min GFR 50-70ml/min GFR > 80ml/min 
Exclusion criteria Previous kidney transplant, kidney donor or 
blood-borne disease 
Known heart disease. Current 
treatment for hypertension, 
hyperlipidemia or diabetes. 
Blood- borne disease. 
 
Exclusion criteria for all groups: Active infections. Current immunosuppressive therapy with steroids 
or cytotoxic drugs.  Age criteria: 18-62 years. 
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Table 2 Demographic characteristics of the PROGRESS study at inclusion 
 Mild-
Moderate 
CKD 
(stage 2-3) 
Advanced 
CKD 
(stage 4-5) 
Controls p-value n 
GFR ml/min x 
1.73m2 
60.1 ± 5.2 15.3 ± 3.9 99.3 ± 12.0 <0.001 
Age, years 47 ± 11 49 ± 12 48 ± 11 0.60 
Male, n (%) 33 (61)* 29 (59)* 33 (61) 0.97 
Height, m 1.74 ± 0.09 1.73 ± 0.10 1.76 ± 0.09 0.3 
Weight kg 78.7 (18.7) 77.7 (16.6) 77.1 (12.9) 0.88 
BMI 25.7 ± 4.9 26.0 ± 4.2 24.9 ± 3.5 0.42 
Heart rate 
(beats/min) 
65 ± 13 65 ± 13 65 ± 10 0.9 
SBP (mmHg) 123 ± 15 130 ± 20 117 ± 12 <0.001 
DBP (mmHg) 77 ± 10 78 ± 10 73 ± 9 0.03 
Current or past 
smoker, n (%) 
27 (50.9) 25 (51.0) 20 (37.7) 0.29 
Diabetes, n (%) 11 (20.4) 
IDDM 6 
NIDDM 5 
7 (14.3) 
IDDM 1 
NIDDM 6 
- 0.42 
CKD = chronic kidney disease; GFR = glomerular filtration rate; n = number; BMI = body mass index; BSA = body surface 
area Values reported as number (percentage), or mean ± standard deviation or median (interquartile range) for skewed 
variables. p value: analysis of variance (ANOVA) or Kruskal–Wallis test (continuous values), chi-square (categorical 
values). *=matched for age and sex 
 
 
Available clinical data for association studies and parameters ranging from inflammatory 
markers, biochemical markers, nutritional status, general health status, bone density status 
(DEXA) and cardiovascular investigations with blood pressure, effort test, echocardiography, 
carotid Doppler, 24-hour blood pressure registration and mortality data were collected.  
The final participant was enrolled in 2009 and group 2 and 3 of the cohort were monitored 
during a follow-up time of 5 years. Of the 54 healthy controls, 30 were randomly selected 
from the Swedish Total Population Register and 24 were recruited through the website of the 
regional university hospital. Interviews were performed with potential healthy controls 
concerning prior health history and medication. One included patient did not complete the 
baseline echocardiography and was excluded from the echocardiography study (paper II) 
together with her control.  
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Table 3 Cause of CKD and pharmacological treatment in the PROGRESS cohort 
Diagnosis of CKD, n 
(%) 
CKD 2 – 3  
 (n = 54) 
CKD 4 – 5  
(n = 49) 
p value, n  
Hereditary/ congenital 
diseases  
14 (26)  13 (27)  0.94 
Primary 
glomerulonephritis  
17 (32)  12 (25)  0.43 
Secondary 
glomerular/systemic 
disease  
9 (17)  10 (20)  0.63 
Miscellaneous/ 
unknown  
14 (26)  14 (29)  0.76 
Medication, n (%)  
Diuretics  12 (22) 34 (69)  < 0.001 
ACE inhibitors  23 (43)  29 (59)  0.093 
Angiotensin II 
receptor blockers  
22 (40)  23 (47)  0.53 
Beta-blockers  11 (20)  20 (41)  0.024 
Calcium channel 
blockers  
10 (19)  28 (57)  < 0.001 
Statins  13 (24)  32 (65)  < 0.001 
ACE = angiotensin converting enzyme; Values reported as number (percentage), or mean ± standard deviation or 
median(interquartile range) for skewed variables. p value: analysis with Mann- Whitney U-test or t-test   
 
 
The category “Systemic disease” included nefroangiosclerosis, diabetic nephropathy and two 
cases of SLE but no case of vasculitis in group 2. None of the Lupus patients expressed an 
elevated CRP-level at any of the measuring points (hsCRP year 0 – year 3 - year 5: 0.8 -0.87 - 
0.83 mg/l and 0.8 - 0.6 - 0.46 mg/l respectively). Nor did the only SLE diagnosed participant 
in group 1 have an elevated CRP at baseline (hsCRP 0.98 mg/l).  
 
Table 4 DEXA and lipid data from the PROGRESS cohort, all groups at baseline 
Variable Controls  
GFR 99.3 ± 12.0  
(n = 54) 
CKD 2 – 3  
GFR 60.1 ± 5.2  
(n = 54) 
CKD 4 – 5  
GFR 15.3 ± 3.9 
 (n = 49) 
p value, n  
BSA, m2 1.92 ± 0.19  1.92 ± 0.24  1.91 ± 0.23  n.s 
Body fat 
percentage 
23(8) 27(9) 27(11) n.s 
BMC g 2570 (413) 2537 (660) 2380 (434) n.s 
BMD g/cm2 1.2 (0.1) 1.2 (0.2) 1.1 (0.1) 0.02 
T-score 0.3 (1.0) 0.4 (1.4) -0.3 (1.3) 0.01 
Z-score  0.8 (1.1) 1.0 (1.4) 0.4 (1.3) n.s 
Total Cholesterol 5.14 ± 1.20  4.98 ± 1.04  4.63 ± 1.02  n.s 
LDL 3.36 ± 1.12  3.15 ± 0.93  2.64 ± 0.93  0.002  
HDL 1.33 ± 0.41  1.26 ± 0.40  1.19 ± 0.37  n.s 
Triglyceride  1.0 ± 0.62  1.38 ± 0.84  1.7 ± 0.84  < 0.001  
hsCRP 0.90 (0.46 – 2.30)  2.30 (1.10 – 4.10)  1.60 (0.96 – 3.00)  0.009  
DEXA variables all reflect total body measurement., BSA- Boy Surface Area m2 BMC = Bone Mineral Content g/cm, BMD 
= Bone Mineral Density T-score= number of SD above or below the mean for a healthy 30-year old with the same sex and 
ethnicity, Z-score = score number of SD above or below the mean for the same sex, age and ethnicity as the patient. Lipids 
measured in mmol/L. LDL = low-density lipoprotein; HDL = high-density lipoprotein; hs-CRP = high-sensitive C-reactive 
protein in mg/l; Mean (SD) Differences in mean values analyzed with ANOVA-test (F-test). p>0.05 = n.s             
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Paper II  
All 103 patients from both CKD groups (stages 2-3 / mild-to-moderate dysfunction or stage 4-
5 / advanced renal failure) in the Progress 2002 cohort were included in a baseline study of 
echocardiographic variables compared with the healthy controls.  
Paper III 
Included the patients from Group 2 (mild-moderate CKD) and the healthy controls from the 
PROGRESS cohort and collected data at baseline, year 3 and year 5 in a prospective follow 
up study. 
Paper IV 
All 103 CKD 2-5 patients and 53 healthy controls from the PROGRESS cohort were 
examined for FGF-23 levels, biochemical profile, inflammatory markers and cellular data in a 
cross-sectional study at year 0 (baseline). 
 
 
 
4.2  ROUTINE LABORATORY AND CLINICAL MESUREMENTS 
 
Generally, plasma and serum samples were spun and stored at -70° C. Laboratory results and 
clinical data were gathered from the patients’ records at the time of inclusion and at follow up. 
Analyses for creatinine were executed using routine methods.  
All participants in the PROGRESS cohort had glomerular filtration rate (GFR) measured by 
iohexol at inclusion but only the CKD stage 2-3 patients had iohexol analysis repeated at 3rd 
and 5th year. Filtration capacity in healthy controls at 3rd and 5th year was calculated with 
creatinine based formulas. In paper II-IV we used the CKD- EPI formula since this has been 
shown to prove a more exact estimate of kidney function in the range of mild CKD. 
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4.3 THE SKIN CHAMBER METHOD  
 
A fundamental step in the host defense mechanism is when polymorphonuclear leukocytes 
migrate into the tissue. The transmigration process is intricate and includes several 
consecutive steps. The skin chamber technique is a well-documented method providing means 
to study extravasated leukocytes in a local exudation without systemic inflammatory 
responses171. A local inflammatory reaction provokes the leukocytes to leave the blood stream 
and wander to sites where they can be gathered. Skin blisters are induced by suction and a 
gentle heating loosens the epidermal layer from the underlying dermis on the volar surface of 
the forearm172. The eruptions are produced without harming the capillaries or dermal tissue. 
Blister roofs are removed and plastic chambers containing a chemoattractant, autologous 
serum or PBS, are mounted over the raw wound surfaces173. Analysis of temporal changes of 
the cell population in the chamber has shown that mononuclear cells appear early but are soon 
outnumbered by polymorphonuclear cells that constitute 90-98% of the cells after 10-24 
hours. Transmigrated cells in our studies were collected and analyzed after an incubation time 
of 10 hours.  
 
 
 
Figure 4 Skin chamber technique with mounted plastic chambers 
 
 
4.4 LUMINEX METHOD 
Soluble inflammatory mediators; such as cytokines and chemokines in serum and chamber 
fluid in paper I, III and IV were performed on the Luminex-100 system and assessed by 
Milliplex 26-plex (Millipore Corp). This method has the advantage of being performable on 
very small sample volumes, with a lower detection limit of 3 pg/ml. Briefly, distinctly dyed 
microspheres are coated with capture antibodies that will catch the specific analyte of the 
investigated sample. Added fluorescent detection antibodies are then distinguished by a laser 
that discriminate both the colour of the microsphere and each tagged detection antibody. 
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4.5 FLOW CYTOMETRIC ANALYSIS 
 
FACS (fluorescence-activated cell sorting) or flow cytometry measure cell characteristics by 
laser-scanning cell suspensions flowing through the instrument. Data on cell size and 
granularity are provided by the instrument recognizing different leukocyte cell populations by 
their light-scattering properties. The cells ability to refract and reflect light respectively differ 
between different types of leukocytes. 
A two-parameter scatter plot histogram is produced by the computer presenting the different 
populations of white blood cells. Cell size is expressed as forward scatter (FSC) on the y-axis 
whereas granularity and membrane dimension condensed as density are expressed as side 
scatter (SSC) on the x-axis. With flouro-chrome-marked antibodies more precise details about 
the cells can be revealed when the laser excitation makes them emit light of different wave 
length (represented with a specific color). 
In paper I, III and IV monocytes and granulocytes were selected by flow cytometry and their 
adhesion molecules expression identified in addition to their oxidative metabolism (hydrogen 
peroxide formation), all measured and quantified as mean fluorescence intensity (MFI). 
 
 
 
 
 
 
 
Figure 5 Principles of cell separation by cytometry 
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4.6 TRANSTHORACIC ECHOCARDIOGRAPHY 
 
Transthoracic echocardiography is used to evaluate cardiac function through measuring 
dimensions such as left ventricular mass, wall thickness and diastolic and systolic function. 
TDI – Tissue Doppler Imaging describe tissue movement and velocity.  
Left ventricular ejection fraction (LVEF) and AV plane measurement have traditionally been 
used to assess left ventricular systolic function estimating diagnostic and prognostic 
outcome174–176. Global left ventricular longitudinal strain (GLS) obtained by using two-
dimensional speckle tracking analysis or TDI assessing longitudinal LV function by s´(s′  = 
peak systolic mitral annular velocity) have been shown to be more reproducible and superior 
to LVEF in predicting cardiac events and all-cause mortality177.   
Left ventricular diastolic function and filling pressure can be measured using Doppler 
recordings of transmitral and pulmonary venous flow velocities178. TDI measurement of early 
passive transmitral inflow velocity (E) and the rate of the atrial component of LV filling (A) 
joined in the E/A ratio show a reduced value with declining diastolic function179. A ratio 
between diastolic flow and wall velocity, called the E/e′ ratio (the early diastolic filling rate 
(E) to pulsed tissue doppler velocity of the septal mitral annulus during passive filling (e′)), 
has been demonstrated to effectively, and with high reproducibility, assess diastolic 
function180–182. Moreover, in diabetic patients, the E/e′ ratio has been shown to independently 
envisage cardiac failure and mortality182,183 
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4.7  ADDITIONAL METHODS (featured Paper) 
 
Analysis of surface molecules (I, III-IV)              ¤ Performed by labeling leukocytes with 
flourochrome conjugated antibodies.  
Cell counts (I, III-IV)                                            ¤ Determines total cell count and     
distribution of individual cell types. 
Oxidative Metabolism (IIII-IV)                            ¤ Examination of intracellular H2O2 
production after fMLP stimulation by 
DCFH-DA system and flow cytometry. 
Immunoassay (I)                                            ¤ Determines the concentration of pro-
inflammatory molecules in serum and 
chamber exudates by commercially 
available assays (ELISA) 
In vitro activation (I, III-IV)                                 ¤ Studies of adhesion molecule expression 
on leukocytes after fMLP or PMA 
stimulation  
In vitro incubation with FGF23 (IV)                     ¤ Studies of adhesion molecule expression 
on leukocytes after FGF23 treatment 
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5  STATISTICAL ANALYSIS 
 
 
Descriptive statistics were utilized to characterize the study populations. Categorical variables 
were expressed as frequencies (%) and proportions. Continuous variables were summarized as 
mean (±SD) for normally distributed data or median values (IQR) for non-normally 
distributed values. Categorical variables were stated as percentages. P-values were calculated 
from Chi2-tests (missing observations omitted) and Student’s t-test for the categorical 
variables and continuous variables, respectively.  
A P value <0.05 for a two-tailed test was considered significant.  
 
 5.1   PAPER I 
Results were expressed as mean ± standard deviation for the normally distributed data; age, 
BMI, creatinine, eGFR, CRP, hemoglobin, PTH, phosphorus and albumin. Non-parametric 
data; cellcount, CD16+, CX3CR1 and soluble factors were presented as median and 25-75% 
interquartile range. Box plots represent 25-75% interquartile range with a line at the median 
and bars at the non-outlier values. Statistical analysis and comparison between groups were 
performed using Mann Whitney U-test.  
 
5.2   PAPER II 
Results are presented as number, percentage, mean and standard deviation (SD). Group 
comparisons were performed using one-way analysis of variance (ANOVA), Tukey’s post 
hoc test and chi-square test (v2) where applicable. 
 
5.3   PAPER III-IV 
Normally or non-normal distributed biochemical data, cytokine/chemokine levels (Luminex), 
adhesion molecule expression and respiratory burst cell data, were assessed graphically by 
histogram plots with associated kurtosis and skewness tests, and by Shapiro-Wilk test. 
Potential outlier- values were examined graphically by box plotting the data. An outlier was 
defined as an absolute value bigger than 3.5 x SDs above or below its calculated mean, and an 
absolute value bigger than 10 x iqr (the inter-quartile range) from its calculated median.  
In Paper III, data from year 0 (baseline), year 3, and year 5, statistically significant differences 
between the groups were assessed by Student's t-test and Mann Whitney U test. Delta values 
(Paper III), were calculated for Luminex, and cell data according to the formula:  
Yidelta = Xit=5 – Xit=0, where X is the measured value at time t for individual i. 
Additionally, generalized linear regression models were calculated to compare and quantify 
differences between the study groups. Comparisons of mean and median differences between 
all groups simultaneously (multiple comparisons testing) were done by ANOVA, and Dunn’s 
testing, an extension to the Kruskal-Wallis test respectively. P-values were adjusted by 
Bonferroni correction or Benjamini-Hochberg correction 184 . The overall significance level α 
was set at 0.05.  Analyses of correlations between FGF-23 levels and biochemical, Luminex, 
and cell data in Paper IV, were performed by Spearman’s rank and Kendall’s correlation.  
31 
6  RESULTS AND DISCUSSION 
 
6.1  EXPRESSION OF ADHESION MOLECULES 
  
6.1.1 CD16 on transmigrated and peripheral monocytes (I) 
 
Patients with CKD stages 4-5 had an increased percentage of CD16+ monocytes both in the 
peripheral circulation and at sites of induced interstitial inflammation. The ratio of the 
percentage of CD16+ monocytes between the peripheral circulation and the interstitial 
inflammatory site in the two studied groups were comparable, indicating similar 
transmigration capacity of the CD16+ monocytes in CKD patients and healthy controls. The 
higher accumulation rate at the interstitial inflammation in CKD patients might be a 
consequence of the increased peripheral pro-inflammatory CD16+ pool. 
 
 
 
Figure 6 Flow cytometric charts of CD16+ expression on monocytes in circulation and chamber fluid in CKD 
patients and controls respectively 
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Figure 7 Boxplot showing the elevation of CD16+ monocytes in CKD patients compared to healthy 
controls. * = p value < 0.05 and *** = p value < 0.001. 
 
Several studies have reported an increase of circulating CD16+ monocytes in CKD185,186 and 
CD16+  monocytes have been found to associate to CV events hence believed to be involved 
in human atherosclerosis154,187. HDF treatment on the other hand, has been shown to reduce 
the percentage of CD16+ cells188.  This study demonstrates an increased percentage of pro-
inflammatory CD16+ monocytes both in blood and in the inflammatory interstitial site in 
patients with advanced CKD. 
 
 
6.1.2 CX3CL1 levels and CX3CR1 expression on monocytes (Paper I) 
 
Fractalkine, CX3CL1, is a membrane anchored chemokine released from the cell surface by 
proteolysis. It binds the fractalkine receptor CX3CR1 and through these dual forms, functions 
as a chemokine as well as an adhesion molecule for a wide variety of immune regulatory 
cells130,189,190. CX3CL1 has a highly antiapoptotic effect on human monocytes191. A balance 
between pro-apoptotic and apoptosis-inhibiting factors is necessary for the maintenance of an 
effective immune response without harmful side effects of an excessive neutrophil activation. 
CD16+ monocytes have a high expression of CX3CR1 which enhances accumulation of these 
cells at sites of overexpressed CX3CL1192. In study I we found an expression of CX3CR1 of 
above 90 % on circulating monocytes in both CKD and healthy controls and the expression 
decreased substantially following extravasation, probably as a result of shedding. Patients 
with CKD had a significantly higher concentration of CX3CL1 in both blood and in the 
interstitial fluid, compared to healthy controls. This indicates a facilitated transmigration and 
tissue retention mechanism for the pro-inflammatory CD16+ subtype of monocytes in CKD 
patients. Once the pro-inflammatory monocytes have left the circulation and entered the local 
inflammatory site, they can further stimulate neutrophil recruitment by means of producing 
chemokines and perpetuate inflammation and tissue injury. 
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6.1.3 Expression of CD11b and CD62L on leukocytes (Paper III and IV) 
 
Adhesion molecule CD11b has an important role in leukocyte transmigration, directing innate 
immunity cells to act on invading microbes. In our prospective follow up study (Paper III) on 
mild-to-moderate CKD there were no significant differences in monocyte expression of 
CD11b or CD62L at baseline (year 0), in resting state, comparing patients and controls. These 
findings suggest that monocytes are in a restored state at earlier phases of CKD, reflected in a 
normal expression of CD11b. Interestingly, following stimulation with fMLP, we observed a 
higher expression of CD11b on the surface of patients’ monocytes at baseline. This may 
suggest an inclination of these cells to translocate the intracellular stored CD11b to the 
surface, possibly due to a higher responsiveness of primed cells in the pro-inflammatory 
milieu. In contrast to the baseline value, a significant decline in the CD11b expression 
occurred following stimulation with fMLP, both at 3rd and 5th year. This may reflect an 
inability to mobilize CD11b from the intracellular vesicles or a refractoriness of monocytes 
exhausted by the constant inflammatory burden of renal insufficiency 1,147,157,158,193,194. How a 
lower CD11b expression evolves over time supports our previous studies where we found that 
peripheral resting monocytes from patients with advanced renal disease express a lower level 
of CD11b, when compared to healthy controls158.  A preserved response of monocytes to 
fMLP stimulation was previously found in patients treated with high flux hemodialysis147, 
perhaps indicating a reversibility of this cellular refractory effect by hemodialysis. A low 
response to fMLP may contribute to the elevated susceptibility to infections in CKD patients. 
In Paper IV inactive granulocytes and monocytes from CKD stage 2-5 patients showed an 
elevated expression of CD11b which might reflect an impact of amplified activity of TNFα 
and RANTES on these cells, exposing cells to a higher inflammatory elementary level. 
However, no difference between patients and controls was detected in terms of CD11b 
expression on fMLP stimulated granulocytes while the expression on monocytes was 
increased in patients. Monocytes are in general more inflammatory active and cytokine 
responsive whereas granulocytes exhibit greater impact on host defense and direct immunity. 
There was also a greater interpersonal variability in CD11b expression on monocytes in 
patients as compared to controls, perhaps reflecting fluctuations of cytokine levels.  
CD62L (L-selectin) plays an important role in adhesion of cells to the inflamed endothelium. 
Following adhesion and activation of monocytes, CD62L is rapidly enzymatically cleaved 
and shed from the cell surface195,196. In a previous study we have shown that monocytes from 
patients with severe renal failure express a lower CD62L in periphery158.  
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In Paper III, CD62L expression on monocytes in patients with mild-to-moderate CKD was 
comparable to healthy controls at baseline but had a significantly lower expression both at 3rd 
year and at 5th year of the study. This could imply a better feature of monocytes at an earlier 
phase of the disease, but a lower translocation, or higher shedding of CD62L over time, 
probably due to enhanced production of inflammatory mediators. For instance pro-
inflammatory TNFα enhances shedding of CD62L195–197. The significant increase of TNFα 
over the study years with a simultaneous decrease in CD62L levels, may support this 
hypothesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Expression of CD11b and CD62L in CKD patients and Controls at baseline (y0), year 3 and year 5 
(Paper III). 
 
The counterbalance act of the innate immunity is crucial to avoid tissue damage. The altered 
monocyte function and excessive pro-inflammatory cytokine expression in our CKD 2-3 
cohort might imply consequences of the distorted innate immune system. Alterations in 
chemokine levels as well as in adhesion molecule expression might potentially act either 
harmful or protective. Perhaps there is a dysregulation rather than a dysfunction of the innate 
immunity network, inducing the inflammation in CKD.  
 
 
 
 
 
 
 
 
 
 
 
 
CD62L CD11b stimulated 
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6.2  CHEMOKINES (I, III and IV) 
 
CKD patients are subjected to a state of chronic inflammation198, a condition reflected in 
consequential imbalance of pro-inflammatory and anti-inflammatory cytokines112,152,153,199. 
Alterations occur in both innate and adaptive immune responses in CKD due to inflammation, 
uremia, dialysis procedures and oxidative stress. 
In Paper I, CKD stage 4-5 patients had a significantly higher concentration of TNFα in the 
peripheral circulation compared to healthy controls. However, in the skin chamber fluid, 
concentrations of TNFα and IL-10 were significantly lower in CKD patients compared to in 
healthy controls. In addition, the TNFα/ IL-10 ratio was significantly higher in serum from 
CKD patients compared to in controls.  
The impaired TNFα concentration gradient between the circulation and the interstitial space 
has previously been associated to an increased risk of septicaemia as well as adverse 
outcome200–203. An impaired cytokine gradient might also contribute to decreased leukocyte 
trafficking to secondary inflammatory sites, potentially contributing to the impaired immune 
response and increased susceptibility to infections in CKD.  
Experimental apheresis studies have been shown to effectively restore chemokine gradients, 
leading leukocyte trafficking toward infected tissue and away from healthy organs204 
However, attempts to acute remove TNFα and IL-6 with hemoadsorption have not achieved 
decreased levels post treatment, even though treated subjects had an improved survival. 
Hence, blood purification must instigate some other beneficial immuno-modulating effect, 
with a so far unknown mechanism205. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 TNFα and IL-10 levels in CKD vs Controls in peripheral circulation and chamber fluid from Paper I. 
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In Paper III and IV, there were significantly higher levels of TNF- α, IL-12 and RANTES in 
plasma from patients, compared to in healthy controls. Notably, in paper III, levels of 
chemokines in general tended to fluctuate over time which most likely reflects a variability of 
the inflammatory process. Elevated cytokine levels in advanced CKD are partly due to a 
reduced renal clearance but may also be a result of an increased production from dendritic 
cells that are stimulated by retained toxins153. However, at early stages of renal disease an 
accumulation is less plausible and elevated levels would probably result from an actual 
pathogenic mechanism rather than from a decline in filtration rate.  
Augmented production of pro-inflammatory cytokines such as TNF-α, IL-1, IL-8, IL-15 and 
IL-12 has been shown in both pre-dialysis and in hemodialysis groups, indicating a role of the 
uremic milieu in this process, independent of dialysis treatment199. Elevated levels of pro-
inflammatory cytokines might contribute to enhanced vascular plaque formation as well as 
changes in cardiac function and structure, leading to cardiovascular morbidity. 
 
RANTES modulates migration of monocytes by inducing expression of CD11b/CD18206. 
Elevated levels of RANTES have been associated with sustained inflammation and multiple 
immune-mediated diseases132,207. Moreover, TNFα is known to induce production of 
RANTES under inflammatory conditions131. Aberrant IL-12 expression has been reported in 
infectious, autoimmune, inflammatory conditions and atherosclerosis, modulating the 
adaptive immune response208.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Concentration (pg/ml) of RANTES (CCL5) in plasma from CKD patients and controls at 
baseline, year 3 and year 5 from Paper III.  
 
High levels of RANTES and TNFα are evidence of a high inflammatory state together with a 
poor opposed anti-inflammatory regulation in CKD patients142. These cytokines might serve 
as potential surveillance biomarkers to monitor development of inflammation in kidney 
failure. 
   
Controls 
CKD 2-3 
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6.3  OXIDATIVE METABOLISM 
 
There was no significant difference in H2O2 production at baseline (Paper III and IV) or at 
follow up, between patients and healthy controls in Paper III, but stimulation with fMLP 
resulted in a significantly lower oxidative burst response in monocytes over time in CKD 
patients.  
 
 
 
 
Figure 11 H2O2-production measured as Oxidative Metabolism (OM) (MFI) median in (fMLP)-
stimulated cells in CKD patients and controls at baseline, year 3 and year 5. 
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6.4  FGF23 (Paper IV) 
 
  6.4.1 Levels of FGF23 
 
An elevation of FGF23 is the earliest detectable serum abnormality in patients with CKD-
MBD (mineral and bone disorder). As kidney function decreases FGF23 increases gradually, 
reaching more than 200 times the normal levels at advanced CKD209. Accordingly, the FGF23 
concentration in Paper IV varied markedly among CKD patients and data confirmed a strong 
inverse correlation between FGF23 and kidney function. As anticipated, there were 
significantly higher levels among CKD patients as compared with healthy controls.  
The FGF-23 levels were right-skewed and were natural log-transformed for further analysis. 
Median FGF-23 level in subjects with normal kidney function (controls) was 17.5 RU/ml 
(IQR 11.1), in patients with mild-to-moderate CKD 26. 3 RU/ml (IQR 26.2) and in severe 
CKD 175.8 RU/ml (IQR 439.7). 
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Figure 12 Diagram of the FGF23 distribution depending on kidney function in a sub-study from Paper IV. 
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6.4.2 FGF23-correlations 
 
The relationships between FGF23 and a broad set of inflammatory and non-inflammatory 
biomarkers were investigated. Importantly, the established relationship between FGF23, renal 
function and markers of mineral metabolism was corroborated. Association studies between 
FGF23 and non-inflammatory biomarkers showed significant correlations between FGF23 
and phosphate, PTH and calcium but not with CRP or fibrinogen. In addition, FGF23 level 
was associated with albuminuria (UAE/urinary albumin excretion), a prognostic marker for 
disease progression210–212. This is interesting since recent studies may indicate presence of the 
relevant FGF23 receptor(s) in podocytes213. The pro-inflammatory cytokine TNF-α was 
significantly increased in CKD patients as compared to in healthy controls, but did not 
correlate to FGF23 level. Moreover, significantly higher levels of transmigration triggering 
chemokine RANTES and immune response initiating IL-12 were found in CKD patients as 
compared to in controls and were also associated to rising FGF23 level. 
FGF23 was associated with CD11b expression on resting granulocytes and monocytes in the 
CKD group, but not with CD11b on fMLP activated cells. This might reflect how FGF23 in a 
cohort including various stages of CKD predominantly exhibits an immune-modulating effect 
through augmented impact on pro-inflammatory cytokines and cell priming which perhaps 
precedes a more direct cell targeting effect on active granulocytes that might develop as 
kidney function deteriorates and FGF23 levels increases.  
Thus, FGF23 levels were associated to elevated chemokines IL-12 and RANTES in CKD as 
well as to leukocyte altered adhesion molecule expression on unstimulated cells.  
FGF23 linkage to inflammatory markers has been described in several studies in both CKD 
and non CKD cohorts100–103. These studies have delivered pieces of information on the 
relationship to inflammation but none have previously analyzed different aspects of innate 
immunity with multiple soluble markers and effector cells simultaneously. 
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Figure 13 FGF23 Correlation plots. Illustrating log-log correlation plots between FGF23 and biochemical 
markers. Six specific plots where we found a statistically significant (p<0.05) difference of the FGF23-marker 
correlation between groups. Scale values show orders of magnitude instead of units. For example, considering 
the FGF23-Phosphate plot, an observation (individual) with the highest number on the x-axis had the highest 
measured phosphate level. 
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6.4.3. Cell incubation with FGF23 protein 
 
Given a potential dual effect of FGF23 the aim was to analyze the direct effect on neutrophil 
function related to transmigration, focusing on expression and mobilization of CD11b. In 
incubation experiments in vitro, leukocytes from healthy volunteers were exposed to different 
levels of FGF23, simulating conditions of gradually worsening renal function. Granulocytes 
exposed to high levels of FGF23 showed significantly lower expression of CD11b both in 
resting as well as in fMLP stimulated cells when compared with cells unexposed to FGF23.  
An impaired granulocyte response to fMLP can theoretically result in either a diminished 
granulocyte recruitment subsiding host defense, but perhaps also trigger an anti-inflammatory 
effect mediated by a down regulated cell response.  
One might speculate that FGF23 possibly affects innate immunity in a dose dependent 
manner. Initially at moderately elevated levels, FGF23 may induce production of pro-
inflammatory chemokines. As a result, host defense would be strengthened with chemokine 
endorsed CD11b expression, priming resting granulocytes and monocytes as well as activated 
monocytes. Conversely, exposure to high concentrations of FGF23, equivalent to levels in 
advanced CKD, may operate directly through a receptor dependent pathway on granulocytes 
to downregulate CD11b and hereby result in impaired host defense mechanisms. Granulocyte 
recruitment appears to be compromised by high FGF23 exposure. However, FGF23 incubated 
monocytes showed no difference in CD11b expression. This cellular discrepancy in response 
might indicate diverging principle target molecule of FGF23. Neutrophils predominantly 
express the migration mediating FGF receptor FGFR2214 whereas monocytes display high 
expression of FGFR1215. Thus an exposure to high concentrations of FGF23, equivalent to 
levels in advanced CKD, may operate directly through a receptor dependent pathway on 
granulocytes to downregulate CD11b and hereby result in impaired host defense mechanisms.  
 
 
 
 
Figure 14 Granulocyte and monocyte fMLP response in CD11b expression (MFI) with and without FGF23 
exposure in vitro. 
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6.5  CARDIAC STRUCTURE IN CKD (Paper II) 
 
It is clear that there is a close relationship between CKD and increased risk of cardiovascular 
disease. From early stages to end stage renal disease (ESRD); coronary artery disease, 
arrhythmias, congestive heart failure and sudden cardiac death represent the main causes of 
morbidity and mortality in CKD. With progressive CKD a more compensatory hypertrophy, 
dilation and dysfunction of the heart (uremic cardiomyopathy) might occur as a consequence 
of myocardial apoptosis, decreased myocardial capillary density and intermyocardial 
fibrosis216. Echocardiographic abnormalities such as LVH, impaired EF and increased end-
systolic and end diastolic LV volumes have been reported from early to severe stages of 
CKD52,53,217. However, the exact pathophysiological mechanisms behind the high prevalence 
of cardiovascular disease in earlier stages of renal impairment remain insufficiently 
investigated. In our study (Paper II) of cardiac structure at different stages of CKD we found 
alterations even in the mild-to-moderate CKD group. 
 
 
6.5.1 Systolic function 
 
CKD patients had a higher prevalence of LVH compared with the controls; 30% in CKD 2-3, 
and 37% in stage 4-5 as compared to 13% in controls. There was however no significant 
difference between the groups in LVEF calculated with Teichholz method but systolic 
dysfunction in terms of impairment of longitudinal systolic movement measured by AV-plane 
method with TDI showed lower longitudinal systolic function in CKD patients as compared 
to controls, as assessed by atrio-ventricular plane displacement and s´.  
 
 
 
 
 
Figure 15 LVH prevalence with Teichholz 2D echocardiography showed no significant difference between the 
groups whereas LVMI were higher in CKD patients as compared to controls. 
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6.5.2 Diastolic function 
 
There was no significant difference in traditional characteristic measurements of diastolic 
dysfunction, such as transmitral inflow pattern (E/A ratio) or left atrial size. With TDI method 
however, CKD patients had significantly lower septal diastolic velocity (e´) and higher mitral 
mean E/e´ compared to controls, indicating altered diastolic function in the patients. This 
indicates an impairment of diastolic function in the patients with CKD, although the majority 
had preserved LVEF. These changes in diastolic variables may be precursors of clinical heart 
failure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 TDI data showed had significantly lower septal diastolic velocity (e´) and higher mitral mean E/e´ 
compared to controls, indicating altered diastolic function in the patients. 
 
Systolic dysfunction in late stages of CKD is associated with increased mortality and CV 
events even in asymptomatic patients 218. In non-dialysis CKD diastolic dysfunction has a 
prevalence of 29% whereas numbers up to 80 % have been found in the dialysis population.219 
With TDI, we found alterations in systolic and diastolic myocardial function in the CKD 
patients compared to the healthy controls. Several previous studies have demonstrated 
changes in LV geometry in patients with CKD but association between kidney function and 
impaired global systolic function (LVEF) measured by traditional echocardiographic methods 
has not been established. After adjusting for potential confounders the Chronic Renal 
insufficiency Cohort (CRIC) study showed association between reduced renal function and 
abnormal cardiac structure, but not to systolic or diastolic function219. Our findings are 
consistent with previous studies showing that TDI is a more sensitive tool than conventional 
echocardiography for the detection of impaired diastolic function in the patients with 
CKD72,220. Echocardiographic diagnosis and assessment of alterations in cardiac structure in 
early CKD have clinical implications on when to initiate optimization of blood pressure 
control, renal anemia, treat secondary hyperparathyroidism and volume overload. These 
medical interventions can to some extent reverse LVH and thereby save lives and suffering in 
CKD patients.  
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6.6  DEVELOPMENT OF GFR IN THE PROGRESS COHORT (Paper III) 
 
The healthy control group (Group 3) in the PROGRESS study decreased in GFR over the five 
years of study to a greater extent than anticipated, while the mild to moderate CKD patients 
lost GFR to a lower degree than expected. Both groups lost the filtration capacity at the same 
rate; a mean GFR loss of 10 ml/min/1.73m2 over 5 years.  
The frequent therapeutic interventions in the CKD-group with more regular follow up and 
aggressive treatment of hypertension, hyperlipidemia and proteinuria, might very well have 
halted the progression rate. There is also a problem with predicting the outcome of GFR 
development in a relative kidney competent group. For example, some participants were 
included at, as it would turn out, an uncharacteristically low GFR, only to recover renal 
function and not progress any further. 
 
 
‘ 
 
Figure 17 Progress in eGFR in CKDEPI CKD 2-3 (yearly) and controls (year 0, 3 and 5). CKD 4-5 at baseline 
(year 0). 
 
 
 
Figure 18 Progress of GFR (ml/min) in the mild-to-moderate CKD-group of the PROGRESS cohort. Data 
displayed both with 3 types of eGFR methods (MDRD, CKDEPI and LundMalmöRevised formula) as well as 
iohexol clearance. Presented in delta value (value year 5 minus value at baseline year 0). 
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Patients with diabetes as CKD diagnose were relatively few in the cohort which also can have 
slowed down the median progression rate of the CKD group, since patients with diabetic 
nephropathy generally loose kidney function faster than other CKD groups.  
 
 
 
 
Figure 19 Development of Urinary Albumin Excretion (UAE) in controls and patients CKD 2-3 over the 5 
study years in the PROGRESS cohort. 
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7   GENERAL DISCUSSION AND METHODOLOGICAL 
CONSIDERATIONS 
 
7.1  STUDY DESIGN 
 
All the studies we performed were cohort studies but in Paper I we used a case control design. 
Paper II and IV were based on a cross sectional study of baseline data from the observational 
single-center PROGRESS study. In paper III we used prospective observational data with 5 
years follow up from the PROGRESS cohort.  
Observational studies investigate events that take place within a population without an 
experimental design. According to this set up exposed and non-exposed subjects are most 
likely different. Adjustment for differences between the divers groups in an observational 
study is needed. Case-control studies are usually performed when the studied disease is rare 
but the events fairly common. The method is to select cases that have developed the disease 
and compare them with healthy controls from the same study base. Differences between 
patients and controls have to be adjusted for by logistic regression analysis. Since we wanted 
to obtain the same sex and age distribution, the controls were matched on these variables.  
 
   
7.1.1 Selection of cases and controls 
 
Incident CKD cases would by definition imply newly diagnosed, which is problematic since 
CKD show so few early signs. This is resolved by using a set predefined GFR level or range 
and by this define incident as when a patient passed the predefined upper inclusion value. 
Prevalent CKD cases includes all patients living with CKD within a defined area, which 
makes the group more heterogeneous since there is an over-representation of patients with 
milder and slower progressing disease. This is why incident CKD more precisely gives a 
picture over how progression rate develops. 
An advantage of our study cohort is the high attendance of the participants and the fact that 
the non-selective referral policy concerning disease severity, makes it possible to follow 
patients during many years which reduces the patients lost to follow up. 
Participants in both cohorts were predominantly white Caucasian upper middle aged patients 
without inflammatory disease and great heterogeneity concerning etiology to CKD, why 
generalization of our results to other patient groups must be done with caution. 
There are of course some study limitations. The sample size of the PROGRESS study of 49 + 
54 patients and 54 controls may have been underpowered to demonstrate potential 
associations. Also, we were not able to ascertain the duration of comorbid conditions, such as 
hypertension and diabetes.  
In the skin chamber cohort, 12 patients were included, since several previous experiences in 
the field have shown that small patient samples demonstrate significant differences. 
47 
  7.1.2 Cohort studies 
 
In our third paper the PROGRESS group was used as a prospective cohort study where we 
followed the individuals prospectively and registered events occurring along the way. The 
difficulty with cohort studies is that they generally demand a large number of participants to 
secure that enough events occur. In addition, they are time consuming and expensive to 
manage. Research on CKD has its obstacles with the large individual variability in disease 
causes and manifestations as well as consequential differentiating set point of diagnosis at 
different CKD stages. Circumstances leading to insufficient data on duration and progression 
rate from the actual disease onset. Furthermore, as we became aware of with the PROGRESS 
cohort, in the majority of CKD cases, disease progresses slowly, obliging for a long follow-up 
time in order to correctly describe the development and to identify biomarkers that predict 
further progress. In the PROGRESS cohort there was a considerable diversity in disease 
progression rate and for group 2 being at such an early stage of CKD mortality was low and 
few patients progressed to renal replacement therapy (RRT). 
The number of measurements varied between individuals in the research follow up resulting 
in cases lost under the follow up time. At inclusion we had 54 patients with mild to moderate 
CKD and 53 controls, but a reduced turn up rate delivered data from 47 CKD patients and 42 
healthy controls year 3 and somewhat improved figures at year 5, with 49 versus 45 persons.   
  
 
7.2  VALIDITY 
 
Defined as results adhering as close to the true value as possible, validity can either be 
described as internal (inferences) or external (generality – do results apply to settings other 
than those studied?). In general, there is always the question of generalizability of the results 
to the investigated population. How representable are the participants of the intended 
investigated population – for example - patients who start on dialysis have a better outcome 
then those who do not. There are several different systematic errors, biases which need to be 
considered when designing a case-control or cohort study. In paper IV we aimed to strengthen 
our data by a validating strategy. We analyzed correlations between FGF23 and biochemical 
markers that previously have been confirmed in larger studies to have associate with the 
FGF23 levels. We thereafter carried on with association analysis between FGF23 and the less 
well described inflammatory markers. Other potential validity concerns are the technical 
issues in the measurement of inflammatory biomarkers with the Miliplex method. Due to the 
fluctuating nature of cytokine levels, the expression is depending on inflammatory effector 
cell activity. On the other hand, using the Miliplex technique enabled us to analyze 
inflammatory markers portraying different aspects of the inflammatory immune system from 
very modest sample volumes. 
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  7.2.1 Confounding 
 
Confounding may occur if a related factor affects the compared groups in a way which relates 
to and interferes with the studied outcome. A true confounder is not a consequence of the 
studied exposure but has to be associated to both the exposure and disease. Paper II – is 
perhaps high blood pressure and not CKD/ inflammation behind altered diastolic function? In 
Paper II there are confounders as anemia, hyperparathyroidism and hypertension to take in to 
account since they might affect outcome echocardiography data on LVMI. 
In observational studies one needs to be observant of confounding by indication – meaning 
sicker patients are treated more actively than healthier patients. This needs to be adjusted for 
by regression or stratification. However, it is impossible to adjust for everything a 
nephrologist decides and tries in her or his clinic. Moreover, there might be residual 
confounding due to insufficient clinical information on pharmacological interventions or co-
morbidities in addition to unaccounted laboratory parameters. In addition, there were missing 
or incomplete data in our studies on other potentially relevant confounders such as dietary 
intake or timing of prandial factors. Impaired kidney function alters several hormonal 
pathways but it is not fully understood whether these changes play any significant role in 
systemic inflammation or if these enhance kidney injury 221.  
 
 
  7.2.2 Selection bias 
 
Differences might exist between groups already before a study is carried out rendering a 
problem called selection bias, where a preferential recruitment of individuals to the study 
groups might be liable for the observed effect. Socio-economic groups might be more or to a 
lower extent represented at some clinics raising the question of selection bias. However, in 
Sweden this kind of selection bias in unlikely since the national health insurance gives 
basically equal access to health care regardless of income or habitat. Failed or insufficient 
response to treatment with blockers of the RAAS-system with regard to outcome of blood 
pressure and albuminuria most probably reflects pre-existing renal damage, providing, at least 
to some extent, the high predictive value of follow-up measurements for theses variables on 
disease outcome. Lead time bias, refers to how early detection and diagnosis gives appearance 
of longer survival.  This however, is probably not a relevant concern in our cohort where a 
predetermined GFR level determined inclusion. 
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7.2.3 Misclassification 
 
Differential misclassification can be prohibited by the use of standardized protocols, 
interviews and registry data. Trained professionals at the renal clinic were involved in the 
diagnostic work why misclassifications seem unlikely. The PROGRESS study has several 
strengths in this respect. The demographic data set was robustly characterized. GFR was 
determined by iohexol providing an optimal CKD classification which reduces the probability 
of misclassification and slightly improved the power of the statistical analysis.  
Insufficient exploration of covariates and exposure might lead to non-differential 
misclassifications where both groups are equally affected driving the results towards the null-
hypothesis.  
 
 
7.2.4 Precision 
 
When random sampling results in point estimates that are close, statistical precision is 
obtained. To verify precision one needs to analyze the confidence intervals as we did in Paper 
IV. Even results with high precision might be biased and therefore inaccurate. Sample size is 
crucial to size of standard error. The number of individuals who develop the measured 
outcome and distribution of events across the population are critical factors to obtain 
precision. In small cohorts measuring exact biomolecular markers the sample size is less of 
incidental importance than in prospective case-control studies where sample size is vital. 
Having stated this we are aware of the modest amount of individuals included in the 
PROGRESS. This has made us refrain to certain analyses concerning progress of disease and 
end target organ damage. This would imply a greater number of participants to achieve 
precision. 
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8 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Irrespective of etiology, renal diseases have inflammation and immune system activation as 
common underlying pathophysiological generators. The findings from the present work 
contribute to the conception that there is persistent activation of pro-inflammatory elements of 
the innate immunity at different stages of CKD. The thesis provide a deeper knowledge of the 
mechanisms behind changed leukocyte function and altered cytokine expression in CKD.  Our 
findings with alterations in systolic and diastolic myocardial function in patients with even at 
early stages of CKD, indicate that cardiac involvement is already present in mild-to-moderate 
CKD and may be a precursor of premature cardiac morbidity. Whether the pathogenic 
mechanisms behind the cardiovascular structural and functional effects of CKD also has an 
association to FGF23 remains to be proven.  
 
 
Specifically, based on the different study results, we conclude that:  
 
o In advanced stage of CKD the level of pro-inflammatory CD16+ monocytes 
increase both at local sites of inflammation as well as in the blood. Hence, 
extravasated monocytes may enhance the pro-inflammatory milieu. 
 
o There are alterations in diastolic heart function in mild to moderate CKD. 
 
 
o Patients with CKD have early adhesion molecule alterations and increased levels 
of pro-inflammatory cytokines as well as an impaired ability to induce oxidative 
metabolism. This implies an impaired cell transmigration and a weakened 
response to invading microorganisms.  
 
o FGF23 levels were associated to elevated chemokines IL-12 and RANTES in 
CKD as well as to leukocyte altered adhesion molecule expression at unstimulated 
state but not to oxidative metabolism markers. 
 
 
o Systemic FGF23 levels are associated with multiple markers of the innate immune 
system and high levels suppress the transmigration factor CD11b in granulocytes.  
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Patients with CKD have increased risk for infections and this is an important field of further 
investigation, with the aim to minimize the consequences of secondary blows on an already 
heavily burdened group of patients.  
In continuous analysis of leukocyte function in CKD special efforts should be made to reveal 
the connection to uremic toxins and how they affect the immune system.  
We need to further study the mechanisms behind the refractoriness of neutrophils when they 
encounter inflammatory stimuli, since this reaction most likely is essential for the altered 
leukocyte function in CKD. If we figure out where to suppress inflammation we might 
ameliorate the preservation of target organ function. 
CKD implicates a substantial risk of premature cardiovascular disease that potentially get 
enhanced by pro-inflammatory cells and cytokines as well as by pleotropic acting FGF23 with 
vascular calcification and cardiac remodeling as results. The risk of diastolic and systolic 
impairment in early stages of CKD needs to be recognized and brought to the attention of 
both cardiologists and nephrologists so that we can act on this information and tailor 
treatment according to individual conditions in order to prevent or halt further progress.  
 
In summary, we found increased levels of pro-inflammatory chemokines and CD16+ 
monocytes in advanced CKD while patients with mild-to-moderate CKD displayed early 
alterations in adhesion molecules in addition to the increased cytokine levels. Altered cardiac 
structure and function were found early in CKD and FGF23 levels were associated with 
multiple markers of the innate immunity. 
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9  SUMMARY IN SWEDISH / Populärvetenskaplig sammanfattning 
 
Leukocyterna – kroppens vita blodkroppar, har som främsta uppgift att patrullera i 
blodcirkulationen och uppmärksamma samt oskadliggöra invaderande mikroorganismer eller 
andra potentiella hot. Vävnadsskada eller infektion triggar igång det så kallade naiva 
immunförsvaret direkt. De två viktigaste leukocyterna för detta immunsvar är monocyter 
respektive neutrofiler. Monocyter aktiveras i blodbanan och tar sig sedan till skadad eller 
inflammerad vävnad. Celltransporten från blodet ut i vävnaden kallas för transmigration och 
är en viktig process som innefattar flera kronologiska förändringar i cellfunktionen och 
regleras av vidhäftningsmolekyler på cellytan (adhesionsmolekyler) som CD11b och CD62L 
samt genom svar på signalmolekyler (kemokiner). 
Vi vet sedan tidigare att patienter med njursvikt har en ökad infektionskänslighet och även en 
ökad risk för kardiovaskulär sjukdom. Det har visat sig att leukocyter hos njursjuka fungerar 
sämre med en nedsatt förmåga att hantera invaderande mikroorganismer. 
I arbete I, undersökte vi monocyter både i blodcirkulationen och lokalt i inflammerad 
vävnad. Vi använde oss av en hudkammarmodell som gör det möjligt att studera celler som 
tagit sig ut i vävnaden. Syftet var att studera de utvandrade monocyterna hos patienter med 
kronisk njursvikt och jämföra dem med celler från friska kontroller. Vi kunde påvisa en ökad 
förekomst av en subgrupp av proinflammatoriska monocyter, sk CD16+ celler, hos patienter 
med avancerad njursvikt.  Vi fann även en ökad nivå av de proinflammatoriska 
signalmolekylerna TNFα i blodet samt av fraktalkin i blod och blåsvätska hos de njursjuka. I 
blåsvätskan var både TNFα och IL-10 lägre hos patienterna, som tecken på att immuncellerna 
inte förmådde att fungera optimalt. 
I våra tre följande arbeten har vi undersökt leukocytfunktion, olika inflammationsparametrar 
och hjärtfunktionsmarkörer i en studiepopulation som kallas PROGRESS-studien. Det är en 
prospektiv observationsstudie som sträcker sig över 5 år och som följer utvecklingen av en 
rad kliniska och laboratorieparametrar i en grupp individer med lätt till måttligt nedsatt 
njurfunktion. Dessa jämförs med en grupp ålders och könsmatchade icke njursjuka personer. 
Vid år noll inkluderade vi även data från patienter med avancerad njursvikt vilket gav oss 
möjlighet att utföra tvärsnittsstudier mellan tre grupper (arbete II) och i en större bredare 
njursviktgrupp (arbete IV) år 0. 
I arbete II jämfördes alla tre grupper vid år 0 avseende hjärtfunktion undersökt med 
hjärtultraljud (ekokardiografi) samt med en teknik för att bedöma hjärtvävnades 
rörelsedynamik (Tissue Doppler imaging - TDI). Vi kunde konstatera att det fanns 
förändringar i hjärtats struktur och fyllnadsmekanik både hos patienter med avancerad 
njursjukdom och ibland de med måttligt nedsatt njurfunktion. 
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Arbete III koncentrerades på att följa monocytfunktion och inflammatoriska markörer över 
tid hos gruppen patienter med mild till måttlig kronisk njursvikt jämfört med de friska 
kontrollerna. Vi fann förändringar i uttryck av vidhäftningsmarkörer på cellytan och nedsatt 
förmåga till produktion av oxidativa syremetaboliter (vilka cellen använder som 
bakteriedödande vapen). Därutöver var nivåerna av inflammations underhållande cytokiner 
såsom TNFα, RANTES och IL-12 högre hos patienterna jämfört med de friska kontrollerna. 
I arbete IV analyserade vi nivåer av hormonet FGF23 och korrelerade dem till 
inflammatoriska markörer och cell transmigrationsmolekyler hos samtliga patienter (njursvikt 
grad 2-5) och jämförde det med friska kontroller. FGF23 ökade med avtagande njurfunktion. 
Vi fann att FGF23 nivåer var korrelerade till uttryck av chemokiner som RANTES och IL-12 
samt till högre urinutsöndring av albumin, parathormon och fosfat hos CKD-patienterna 
jämfört med hos de friska kontrollerna. Inkubering av celler från friska donatorer med FGF23 
protein i provrör nedreglerade ytmolekyler för transmigration på neutrofila celler. 
 
Sammanfattningsvis råder ett kroniskt tillstånd med rubbad immunjämvikt vid njursvikt. 
Balansen mellan pro och anti-inflammatoriska faktorer och immunceller snarare än den 
exakta nivån av en enskild markör är av överordnad betydelse för den inflammatoriska 
processen (t.ex. ateroskleros, njursviktsprogress mm). Ytterligare forskning behövs för att öka 
kunskapen om de komplexa mekanismerna bakom hur kronisk njursvikt påverkar 
immunförsvaret och om kopplingarna mellan inflammation, FGF23 och de kardiovaskulära 
konsekvenser som drabbar patienter med njursjukdom.  
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